PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24726F0100Galafold medication — Amicus Therapeutics Us, LLC

Amicus Therapeutics Us, LLC holds $3.4M across 74 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 1 related award under parent 36F79724D0185. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Feb 22, 2027 PoP end — agencies typically plan 12–18 months ahead.

247-Network Contract Office 7 (36C247)

Awarding office

Amicus Therapeutics Us, LLC

Recipient

Feb 22, 2027

PoP end

$228K

Obligated

$228K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amicus Therapeutics Us, LLC — $90

Contract facts

Federal

Contract number36C24726F0100

Also listed as36C247-26-F-0100

Also listed as36F79724D0185-36C24726F0100

Agency247-Network Contract Office 7 (36C247)

Awarding office247-Network Contract Office 7 (36C247)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentAmicus Therapeutics Us, LLC

CAGE867U3

UEIKLJFGENKMD89

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79724D0185

Place of performancePHILADELPHIA PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 23, 2026

PoP end (current)Feb 22, 2027

Obligated$228K

Current value$228K

Potential value$228K

GALAFOLD MEDICATION is a federal award for 247-Network Contract Office 7 (36C247) held by Amicus Therapeutics Us, LLC. Estimated value $228K ($228K obligated). Current period of performance ends Feb 22, 2027. Last award drew 1 bidder. Place of performance: PHILADELPHIA PA.

Recompete timing

Public

● Expiring in 185 days

Current PoP ends Feb 22, 2027 (185 days remaining). Agencies typically plan 12–18 months ahead — at 6.1 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Amicus Therapeutics Us, LLC — $3.4M obligated across 74 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$3.4M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C25926F0001

GALAFOLD 123 MG CAPSULE - NTE

$295K

Nov 14, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24726F0100?

36C24726F0100 (Galafold medication) is a 247-Network Contract Office 7 (36C247) award with a potential value of $228K, currently held by Amicus Therapeutics Us, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C247-26-F-0100?

36C247-26-F-0100 is the dashed form of PIID 36C24726F0100 (Galafold medication), held by Amicus Therapeutics Us, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24726F0100?

247-Network Contract Office 7 (36C247) awarded 36C24726F0100 to Amicus Therapeutics Us, LLC (potential $228K).

Who is the incumbent on 36C24726F0100?

Amicus Therapeutics Us, LLC is the incumbent with $3.4M across 74 related awards in SCOUT’s public footprint. The current period of performance ends Feb 22, 2027.

When does Amicus Therapeutics Us, LLC’s 36C24726F0100 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 22, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action May 5, 2026